Literature DB >> 10738143

Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi's sarcoma.

L Camera Pierrotti1, L Masami Sumita, W Santos Freire, H Hehl Caiaffa Filho, V A de Souza.   

Abstract

BACKGROUND: human herpesvirus 8 (HHV-8) have recently implicated in the etiology of Kaposi's sarcoma (KS), but the pathophysiologic and immunologic interactions between HHV-8 and the human host are incompletely understood.
OBJECTIVE: this paper intends to present partial results of a follow-up study of KS patients, designed to investigate HHV-8 viremia and antibody response.
METHODS: ninety-six paired serial samples (PBMCs and sera) were obtained from 12 aids patients with KS who received HAART prior or just after entry in the study. HHV-8 DNA was detected by nested-PCR and antibodies to HHV-8 latent nuclear antigen (LANA) and lytic antigen by immunofluorescence assay (IFA).
RESULTS: HHV-8 DNA was detected in 33.3% of the first PBMC samples. Among the eight PCR negative patients, four presented positive samples during the follow-up and four remained negative. Five patients had intermittent viremia. Fifteen of the 96 PBMC samples were PCR positive (15.6%). Four of 39 samples (10.2%) from patients classified as stadio II and 11 of the 53 samples (20.7%) from patients in stadio IV were PCR positive (P=0.2). Six patients (50%) had anti-LANA antibodies at the entry in the study. Among the six seronegative patients, two seroconverted 2 months later and four patients remained seronegative during the 5-8 months of follow-up. All patients had anti-lytic antibodies since the first sample.
CONCLUSION: the presence of HHV-8 viremia could be related to the severity of KS and could be intermittent even under HAART. A longer follow-up is needed to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738143     DOI: 10.1016/s1386-6532(99)00078-5

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.

Authors:  Maria Claudia Nascimento; Vanda Akico de Souza; Laura Masami Sumita; Wilton Freire; Fernando Munoz; Joseph Kim; Claudio S Pannuti; Philippe Mayaud
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

2.  Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region.

Authors:  Vanda A U F de Souza; Laura M Sumita; Maria-Claudia Nascimento; Juliane Oliveira; Melissa Mascheretti; Mariana Quiroga; Wilton S Freire; Adriana Tateno; Marcos Boulos; Philippe Mayaud; Claudio S Pannuti
Journal:  J Infect Dis       Date:  2007-08-06       Impact factor: 5.226

3.  Prevalence of human herpesvirus 8 infection in systemic lupus erythematosus.

Authors:  Yu Sun; Shipeng Sun; Wenli Li; Bo Li; Jinming Li
Journal:  Virol J       Date:  2011-05-09       Impact factor: 4.099

4.  The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation.

Authors:  Jie Lu; Subhash C Verma; Qiliang Cai; Abhik Saha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

Review 5.  Human herpesvirus 8--a novel human pathogen.

Authors:  Daniel C Edelman
Journal:  Virol J       Date:  2005-09-02       Impact factor: 4.099

6.  Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma: Is genotype B associated with better prognosis of AIDS-KS?

Authors:  Tania Regina Tozetto-Mendoza; Karim Yaqub Ibrahim; Adriana Fumie Tateno; Cristina Mendes de Oliveira; Laura Massami Sumita; Maria Carmem Arroyo Sanchez; Expedito José Luna; Ligia Camara Pierrotti; Jan Felix Drexler; Paulo Henrique Braz-Silva; Claudio Sérgio Pannuti; Camila Malta Romano
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.